Display options
Share it on

Front Pharmacol. 2017 Feb 21;8:68. doi: 10.3389/fphar.2017.00068. eCollection 2017.

Cafedrine/Theodrenaline (20:1) Is an Established Alternative for the Management of Arterial Hypotension in Germany-a Review Based on a Systematic Literature Search.

Frontiers in pharmacology

Berthold Bein, Torsten Christ, Leopold H J Eberhart

Affiliations

  1. Department of Anesthesiology and Intensive Care Medicine, Asklepios Hospital St. Georg Hamburg, Germany.
  2. Department of Experimental Pharmacology and Toxicology, University Medical Centre Hamburg-EppendorfHamburg, Germany; Germany and German Centre for Cardiovascular Research, University Medical Centre Hamburg-EppendorfHamburg, Germany.
  3. Department of Anesthesiology and Intensive Care Medicine, Philipps-University Marburg Marburg, Germany.

PMID: 28270765 PMCID: PMC5318387 DOI: 10.3389/fphar.2017.00068

Abstract

A 20:1 combination of cafedrine:theodrenaline (Akrinor®) is widely used in Germany for the treatment of hypotensive states during anesthesia and in emergency medicine. Although this drug formulation has been available since 1963, there are few studies relating to its use and many of the data are only available in German. In this article, we summarize the available data and propose mechanisms for the effects of cafedrine/theodrenaline on cardiac muscle cells and vascular smooth muscle cells. Cafedrine/theodrenaline leads to a rapid increase in mean arterial pressure that is characterized by increased cardiac preload, stroke volume, and cardiac output. Systemic vascular resistance and heart rate remain mostly unchanged. Factors which impact the effects of cafedrine/theodrenaline are gender, high arterial pressure at baseline, use of β-blockers, and heart failure. Importantly, the drug is frequently used in obstetric anesthesia without detrimental effects on umbilical cord pH or APGAR score.

Keywords: arterial hypotension: treatment; cafedrine/theodrenaline drug combination; heart frequency; inotropy; obstetric anesthesia; spinal hypotension: treatment

References

  1. J Cardiovasc Pharmacol. 1996 Aug;28(2):208-14 - PubMed
  2. Klin Padiatr. 1977 Mar;189(2):131-6 - PubMed
  3. Ann N Y Acad Sci. 1967 Feb 10;139(3):549-52 - PubMed
  4. Integr Blood Press Control. 2014 Sep 12;7:49-59 - PubMed
  5. Nat Rev Drug Discov. 2014 Apr;13(4):290-314 - PubMed
  6. Arzneimittelforschung. 1958 Apr;8(4):190-6 - PubMed
  7. Arzneimittelforschung. 1962 Aug;12:841-3 - PubMed
  8. Mol Pharmacol. 1983 Mar;23(2):359-68 - PubMed
  9. Chest. 1991 Jun;99(6):1415-20 - PubMed
  10. Fortschr Med. 1978 Mar 30;96(12):653-60 - PubMed
  11. Minerva Ginecol. 2010 Dec;62(6):515-24 - PubMed
  12. Anaesthesist. 2006 Jun;55(6):708-10 - PubMed
  13. Anaesthesist. 2015 Mar;64(3):190-6 - PubMed
  14. Med Welt. 1974 Nov;25(45):1890-2 - PubMed
  15. Z Kardiol. 1975 May;64(5):419-30 - PubMed
  16. Can J Anaesth. 2012 Jun;59(6):604-19 - PubMed
  17. Int J Clin Pharmacol Ther. 1995 Mar;33(3):170-5 - PubMed
  18. Verh Dtsch Ges Inn Med. 1971;77:948-52 - PubMed
  19. Med Welt. 1969 Mar 22;12:649-52 - PubMed
  20. Anaesthesist. 2011 Oct;60(10):916-28 - PubMed
  21. Arzneimittelforschung. 1972 Apr;22(4):698-701 - PubMed
  22. Reg Anaesth. 1985 Jul;8(3):43-9 - PubMed
  23. J Cardiovasc Pharmacol. 2006 Mar;47(3):450-5 - PubMed
  24. Anaesthesist. 1972 Oct;21(10):428-36 - PubMed
  25. Verh Dtsch Ges Inn Med. 1976;82 Pt 2:1132-5 - PubMed
  26. Anaesthesist. 1964 Aug;13:254-6 - PubMed
  27. Anesthesiology. 2013 Sep;119(3):507-15 - PubMed
  28. Mol Pharmacol. 2003 Sep;64(3):533-46 - PubMed
  29. Biochem J. 1973 Nov;136(3):763-71 - PubMed
  30. Br J Pharmacol. 2013 Jun;169(3):528-38 - PubMed
  31. Anaesthesist. 1965 May;14:147-53 - PubMed
  32. Jpn J Pharmacol. 1969 Jun;19(2):194-8 - PubMed
  33. Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):249-53 - PubMed
  34. Arzneimittelforschung. 1972 Apr;22(4):702-6 - PubMed

Publication Types